{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:02Z","timestamp":1772166362201,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01681-8","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:10:46Z","timestamp":1747192246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy in young adults with mature cystic ovarian Teratoma-Derived squamous cell carcinoma: a case series"],"prefix":"10.1186","volume":"18","author":[{"given":"Jing","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-xia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"1681_CR1","doi-asserted-by":"publisher","first-page":"101192","DOI":"10.1016\/j.gore.2023.101192","volume":"47","author":"RA Martel","year":"2023","unstructured":"Martel RA, Marsh L, Lai T, Rodriguez-Triana VM, Moatamed NA, Cohen J. Use of platinum-based chemotherapy and pembrolizumab to treat squamous cell carcinoma arising in a mature teratoma of the ovary in a pre-menopausal woman with negative response: A case report. Gynecol Oncol Rep. 2023;47:101192. https:\/\/doi.org\/10.1016\/j.gore.2023.101192. Published 2023 Apr 20.","journal-title":"Gynecol Oncol Rep"},{"key":"1681_CR2","doi-asserted-by":"publisher","unstructured":"Feng X, Xu L. Rare case of squamous cell carcinoma arising in a recurrent ovarian mature cystic teratoma of a young woman: A case report and review of the literature. Med (Baltim). https:\/\/doi.org\/10.1097\/MD.0000000000010802","DOI":"10.1097\/MD.0000000000010802"},{"key":"1681_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13048-022-01005-0","volume":"15","author":"S Palomba","year":"2022","unstructured":"Palomba S, Russo T, Albonico G, et al. Stage Ia squamous cell carcinoma as the malignant transformation of giant and unusual mature teratoma of the ovary in an elderly patient. J Ovarian Res. 2022;15:68. https:\/\/doi.org\/10.1186\/s13048-022-01005-0.","journal-title":"J Ovarian Res"},{"key":"1681_CR4","doi-asserted-by":"publisher","first-page":"842703","DOI":"10.3389\/fonc.2022.842703","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Qin M, Shan Y, et al. 30-Year experience with 22 cases of malignant transformation arising from ovarian mature cystic teratoma: A rare disease. Front Oncol. 2022;12:842703. https:\/\/doi.org\/10.3389\/fonc.2022.842703. Published 2022 May 9.","journal-title":"Front Oncol"},{"issue":"7","key":"1681_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.pathol.2023.08.001","volume":"55","author":"Y Liang","year":"2023","unstructured":"Liang Y, Ruan H, Yu M, L\u00fc B. Ovarian squamous cell carcinoma associated with teratoma: a report of six cases with genomic analysis. Pathology. 2023;55(7):966\u201373. https:\/\/doi.org\/10.1016\/j.pathol.2023.08.001.","journal-title":"Pathology"},{"issue":"17","key":"1681_CR6","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1038\/s41388-020-1237-0","volume":"39","author":"R Tamura","year":"2020","unstructured":"Tamura R, Yoshihara K, Nakaoka H, et al. XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary. Oncogene. 2020;39(17):3541\u201354. https:\/\/doi.org\/10.1038\/s41388-020-1237-0.","journal-title":"Oncogene"},{"key":"1681_CR7","doi-asserted-by":"publisher","first-page":"789228","DOI":"10.3389\/fonc.2022.789228","volume":"12","author":"XC Song","year":"2022","unstructured":"Song XC, Wang YX, Yu M, Cao DY, Yang JX. Case report: management of recurrent ovarian squamous cell carcinoma with PD-1 inhibitor. Front Oncol. 2022;12:789228. https:\/\/doi.org\/10.3389\/fonc.2022.789228. Published 2022 Mar 9.","journal-title":"Front Oncol"},{"key":"1681_CR8","doi-asserted-by":"publisher","first-page":"100837","DOI":"10.1016\/j.gore.2021.100837","volume":"37","author":"M Wu","year":"2021","unstructured":"Wu M, Bennett JA, Reid P, Fleming GF, Kurnit KC. Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab. Gynecol Oncol Rep. 2021;37:100837. https:\/\/doi.org\/10.1016\/j.gore.2021.100837. Published 2021 Jul 22.","journal-title":"Gynecol Oncol Rep"},{"issue":"7","key":"1681_CR9","doi-asserted-by":"publisher","first-page":"8499","DOI":"10.21037\/apm-20-2429","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, Tang X, Zhuo W. Malignant transformation of ovarian teratoma responded well to immunotherapy after failed chemotherapy: a case report. Ann Palliat Med. 2021;10(7):8499\u2013505. https:\/\/doi.org\/10.21037\/apm-20-2429.","journal-title":"Ann Palliat Med"},{"key":"1681_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.critrevonc.2018.10.005","volume":"133","author":"A Gadducci","year":"2019","unstructured":"Gadducci A, Guerrieri ME, Cosio S. Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A challenging question for gynecologic oncologists. Crit Rev Oncol Hematol. 2019;133:92\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.10.005.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1681_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3348\/kjr.2008.9.5.458","volume":"9","author":"PC Wang","year":"2008","unstructured":"Wang PC, Yang TL, Pan HB. CT images of a malignant-transformed ovarian mature cystic teratoma with rupture: a case report. Korean J Radiol. 2008;9(5):458\u201361. https:\/\/doi.org\/10.3348\/kjr.2008.9.5.458.","journal-title":"Korean J Radiol"},{"issue":"12","key":"1681_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S1470-2045(08)70306-1","volume":"9","author":"A Hackethal","year":"2008","unstructured":"Hackethal A, Brueggmann D, Bohlmann MK, Franke FE, Tinneberg HR, M\u00fcnstedt K. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data [published correction appears in lancet oncol. 2009;10(5):446]. Lancet Oncol. 2008;9(12):1173\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(08)70306-1.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1681_CR13","doi-asserted-by":"publisher","first-page":"300060520981549","DOI":"10.1177\/0300060520981549","volume":"49","author":"X Wang","year":"2021","unstructured":"Wang X, Li W, Kong Y, Liu X, Cui Z. Clinical analysis of 12 cases of ovarian cystic mature teratoma with malignant transformation into squamous cell carcinoma. J Int Med Res. 2021;49(2):300060520981549. https:\/\/doi.org\/10.1177\/0300060520981549.","journal-title":"J Int Med Res"},{"issue":"11","key":"1681_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0929-6646(08)60202-8","volume":"107","author":"RJ Chen","year":"2008","unstructured":"Chen RJ, Chen KY, Chang TC, Sheu BC, Chow SN, Huang SC. Prognosis and treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary. J Formos Med Assoc. 2008;107(11):857\u201368. https:\/\/doi.org\/10.1016\/S0929-6646(08)60202-8.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1681_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12885-019-5393-y","volume":"19","author":"C Li","year":"2019","unstructured":"Li C, Zhang Q, Zhang S, et al. Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review. BMC Cancer. 2019;19(1):217. https:\/\/doi.org\/10.1186\/s12885-019-5393-y. Published 2019 Mar 11.","journal-title":"BMC Cancer"},{"issue":"9","key":"1681_CR16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1097\/IGC.0000000000001375","volume":"28","author":"M Akazawa","year":"2018","unstructured":"Akazawa M, Onjo S. Malignant transformation of mature cystic teratoma: is squamous cell carcinoma different from the other types of neoplasm?? Int J Gynecol Cancer. 2018;28(9):1650\u20136. https:\/\/doi.org\/10.1097\/IGC.0000000000001375.","journal-title":"Int J Gynecol Cancer"},{"issue":"32","key":"1681_CR17","doi-asserted-by":"publisher","first-page":"e34734","DOI":"10.1097\/MD.0000000000034734","volume":"102","author":"X Ji","year":"2023","unstructured":"Ji X, Zhai P, Yang H, Wang H, Wang X. Recurrent squamous cell carcinoma arising in ovary mature cystic teratoma: A case report. Med (Baltim). 2023;102(32):e34734. https:\/\/doi.org\/10.1097\/MD.0000000000034734.","journal-title":"Med (Baltim)"},{"key":"1681_CR18","doi-asserted-by":"publisher","first-page":"101371","DOI":"10.1016\/j.gore.2024.101371","volume":"52","author":"E Peluso","year":"2024","unstructured":"Peluso E, Fowler Edwards W, Marie Tran Janco J. Metastatic squamous cell carcinoma arising from mature teratoma of the ovary: description of multi-modality treatment including incorporation of adjuvant immunotherapy and maintenance PARP inhibitor therapy. Gynecol Oncol Rep. 2024;52:101371. https:\/\/doi.org\/10.1016\/j.gore.2024.101371. Published 2024 Mar 19.","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"1681_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3892\/ijo.2014.2747","volume":"46","author":"P Brachova","year":"2015","unstructured":"Brachova P, Mueting SR, Carlson MJ, et al. TP53 oncomorphic mutations predict resistance to platinum\u2013 and taxane\u2013based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol. 2015;46(2):607\u201318. https:\/\/doi.org\/10.3892\/ijo.2014.2747.","journal-title":"Int J Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01681-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01681-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01681-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:10:47Z","timestamp":1747192247000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01681-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01681-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5684223\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Xinxiang Central Hospital approved this study. Patients signed informed consent for their data to be used for scientific purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all participants, explicitly permitting the collection and use of clinical data for academic research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"100"}}